Everything below concerns deamidation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
Moriarty, Philip. "Au – Gold Nanoparticle". Sixty Symbols. Brady Haran for the University of Nottingham. Point-by-point methods for citrate synthesis and hydroquinone synthesis of gold nanoparticles are available here.
The vast majority of plants are C3, meaning they photorespire when necessary. Certain species of plants or algae have mechanisms to lower the uptake of molecular oxygen by RuBisCO. These are commonly referred to as Carbon Concentrating Mechanisms (CCMs), as they increase the concentration of CO2 so that RuBisCO is less likely to produce glycolate through reaction with O2.
Shankersinh Vaghela (born 21 July 1940) is an Indian politician and former Chief Minister of Gujarat. He was also the Leader of Opposition in 13th Gujarat Legislative Assembly. Vagela started his political career with the Jana Sangh, which later merged into the Janata Party in 1977. After Janata Party split into various fractions, Vaghela became a senior leader of the Bharatiya Janata Party (BJP). In 1996, he broke away from the BJP and formed the Rashtriya Janata Party. He served as the Chief Minister of Gujarat from 1996 to 1997. Later, his party merged with Indian National Congress (Congress). On 21 July 2017, he left Congress and resigned from the post of the leader of opposition. He formed new outfit Jan Vikalp Morcha which contested but did not win any of the seats in 2017 Gujarat Legislative Assembly election. He was a member of the Nationalist Congress Party in 2019-20. He has also served as a Member of Parliament, having been elected to the 6th, 9th (1989-1991), 10th, 13th and 14th Lok Sabhas. He was also a member of the Rajya Sabha from 1984 to 1989. He served as the Union Cabinet Minister of Textiles from 2004 to 2009 in the First Manmohan Singh Cabinet. He represented the Kapadvanj constituency in the Gujarat legislative assembly from 2012 to 2017.
== Research == It is under development by Cara Therapeutics as an intravenous agent for the treatment of postoperative pain. An oral formulation has also been developed. Due to its peripheral selectivity, difelikefalin lacks the central side effects like sedation, dysphoria, and hallucinations of previous KOR-acting analgesics such as pentazocine and phenazocine. In addition to use as an analgesic, difelikefalin is also being investigated for the treatment of pruritus (itching). Difelikefalin has completed phase II clinical trials for postoperative pain and has demonstrated significant and "robust" clinical efficacy, along with being safe and well tolerated. It has also completed a phase III clinical trial for uremic pruritus in hemodialysis patients.
== Function == Pepsinogen is activated into the digestive enzyme pepsin when it comes in contact with hydrochloric acid produced by gastric parietal cells. This type of cell also secretes gastric lipase enzymes, which help digest triglycerides into free fatty acids and di- and mono-glycerides. There is also evidence that the gastric chief cell secretes leptin in response to the presence of food in the stomach. Leptin has been found in the pepsinogen granules of chief cells. Chief cells also produce the acidic mammalian chitinase (CHIA, AMCase), a chitin-digesting enzyme resistant to pepsin digestion. AMCase production requires a local type 2 immune response.
Sources: en.wikipedia.org
At 08:16 the submarine USS Albacore, which had sighted Ozawa's carrier group, had maneuvered into an ideal attack position; Lieutenant Commander James W. Blanchard selected the closest carrier as his target, which happened to be Taihō, the largest and newest carrier in the Japanese fleet and Ozawa's flagship. As Albacore was about to fire, however, her fire-control computer failed, and the torpedoes had to be fired "by eye". Determined to go ahead with the attack, Blanchard ordered all six torpedoes to be fired in a single spread to increase the chances of a hit.
Barry Halliwell, John MC Gutteridge. Free Radicals in Biology and Medicine (5th edn) (Oxford University Press, 2015) ISBN 0-19-871748-2 Barry Halliwell. Chloroplast Metabolism (2nd edn) (Oxford University Press, 1984) ISBN 0-19-854585-1 Reviews
== Targeted protein degradation == In 2001, work from the labs of Craig Crews and Raymond Deshaies described the development of proteolysis-targeting chimeras (PROTACs). Using a small molecule to recruit an E3 ubiquitin ligase to a target protein, this work demonstrated that induced proximity could be used to effect the ubiquitination and proteasomal degradation of a target protein. PROTACs have been frequently applied using the E3 ubiquitin ligases CRBN and VHL to degrade various targets of biological and therapeutic relevance. Multiple groups have sought out additional E3 ligases to co-opt for targeted protein degradation such as FBXO22 and KLHDC2. While PROTACs generally are heterobifunctional compounds linking an E3 ligase binder to a target protein binder, molecular glues also exist that induce protein-protein interactions with E3 ligases, leading to degradation of various substrate proteins. Molecular glues often have been discovered through serendipity, though various methodologies have been explored to expedite the discovery of molecular glues. Biologic modalities for targeted protein degradation have also been explored by fusing E3 ligases to target recognition domains such as nanobodies. These modalities are sometimes referred to as bioPROTACs. While bioPROTACs are advantageous for targeting proteins lacking small molecule ligands, challenges in delivery, pharmacokinetics, and immunogenicity have so far precluded clinical development. Studies exploring different delivery mechanisms have sought to address these shortcomings.
=== 1995 leadership election === John Major was consistently opposed by Eurosceptics in his party (known as the Maastricht Rebels – a small minority of MPs before 1997, but enjoying much wider support among party activists). Heseltine always stated categorically that he would never stand for party leader against Major. In mid-1995 Major challenged his critics to "put up or shut up" by resubmitting himself to a leadership election in which he was unsuccessfully opposed by John Redwood the Secretary of State for Wales. There was speculation that Heseltine's supporters would engineer Major's downfall in the hope that their man would take over, but they stayed loyal to Major. Heseltine had been listening to regular reports about his potential support from his lieutenants Keith Hampson, Richard Ottaway, Michael Mates and Peter Temple-Morris, and in the event of a second ballot hoped to receive Major's endorsement. Peter Tapsell refused to support him because of the European issue. Hampson believed that Heseltine might have won, as did Philip Stephens of the Financial Times. Michael Crick does not agree, pointing out that many of Heseltine's supporters from 1990 had retired from the Commons and the 1992 intake was more right-wing and eurosceptic. Heseltine, who showed his ballot paper to the returning officers to prove that he had voted for Major, commented that "John Major deserves a great deal better than that from his colleagues". Major was re-elected leader.
Recombinant human endostatin is a genetically engineered protein that interferes with the growth of blood vessels to a tumor, thereby starving and preventing the growth of tumor cells. Endu is a modified version of endostatin. Endu has been engineered to contain an additional nine-amino acid sequence to enhance protein purification, solubility and stability and has been shown to improve the function of endostatin. In June 2007, the company acquired an additional 10% equity interest in Yantai Medgenn. The company is conducting Phase IV clinical trials for Endu in approximately 150 hospitals in China.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.